News
ANGN
0.5800
+7.43%
0.0401
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 3d ago
BRIEF-Angion Biomedica Corp On March 9, 2023 Co Novapark Entered Deal Which Terminated Agreement Of Lease, Dated As Of June 21, 2011 - SEC Filing
Reuters · 03/14 23:07
Nasdaq Edges Higher; Neovasc Shares Jump
Benzinga · 01/17 19:50
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/17 18:21
EH, APPH and ATXI among mid-day movers
Seeking Alpha · 01/17 17:56
Dow Tumbles 300 Points; Morgan Stanley Beats Q4 Views
Benzinga · 01/17 17:07
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers' pack
Seeking Alpha · 01/17 15:00
Sibanye Stillwater, iQIYI, Bed Bath & Beyond among premarket losers' pack
Seeking Alpha · 01/17 13:23
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 01/17 12:33
ANGN Crashes Following Merger with Elicio
TipRanks · 01/17 12:28
Angion plummets 20% on merger agreement with Elicio Therapeutics
Seeking Alpha · 01/17 11:00
BRIEF-Elicio To Merge With A Wholly-Owned Unit Of Angion In An All-Stock Transaction
Reuters · 01/17 10:11
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement
Benzinga · 01/17 10:03
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures
Investors Digest More Big Bank Earnings, Weighing on US Equity Futures
MT Newswires · 01/17 08:50
Angion Biomedica Agrees to Merge With Elicio Therapeutics
Angion Biomedica Agrees to Merge With Elicio Therapeutics
MT Newswires · 01/17 06:30
Reported Late Wednesday, Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Benzinga · 12/22/2022 05:15
Angion Biomedica Gets Non-Compliance Notice From Nasdaq
Angion Biomedica Gets Non-Compliance Notice From Nasdaq
MT Newswires · 12/22/2022 03:20
BRIEF-Angion Says Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
Reuters · 12/22/2022 02:55
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
Zacks · 11/24/2022 16:25
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.
Zacks · 11/22/2022 17:53
More
Webull provides a variety of real-time ANGN stock news. You can receive the latest news about Angion Biomedica Corp. through multiple platforms. This information may help you make smarter investment decisions.
About ANGN
Angion Biomedica Corp. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases and acute organ injuries. The Company’s product candidates and programs include ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of biopharmaceutical indications, including cancer, and ANG-3777, a hepatocyte growth factor (HGF) mimetic. Its ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases.